From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA warns: Tolvaptan poses risk for serious liver damage

from Medscape

Tolvaptan, indicated for treating clinically significant hypervolemic and euvolemic hyponatremia, poses the risk of causing irreversible and potentially fatal liver injury, the Food and Drug Administration recently announced. Clinicians should perform liver tests as soon as possible in patients who report fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice or any other symptom that may suggest liver injury, the FDA said. Patients suspected of having liver injury should stop receiving Tolvaptan immediately. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063